微波消融治疗肿瘤免疫效应研究进展
|
摘要
微波消融治疗肿瘤是指用特定频率的电磁波来杀灭肿瘤的治疗方法。微波消融适用于多种组织类型的肿瘤,具有受血流影响小、消融范围广、临床疗效好等优点。微波消融不仅是一种简单通过热效应杀灭肿瘤的手段,其产生的免疫效应在杀灭肿瘤过程中也起到了重要的作用。本文总结微波消融引起的不同类型的免疫效应,并展望微波消融联合免疫治疗在肿瘤治疗中的发展前景。
引文
[1] ZHOU Y,XU X,DING J,et al. Dynamic changes of T-cellsubsets and their relation with tumor recurrence after microwaveablation in patients with hepatocellular carcinoma[J]. J CancerRes Ther,2018,14(1):40-45.
[2] FLORIDI C,DE B I,FONTANA F,et al. Microwave ablationof renal tumors:state of the art and development trends[J]. Ra-diol Med,2014,119(7):533-540.
[3] PLANCHéO,TERIITEHAU C,BOUDABOUS S,et al. In vi-vo evaluation of lung microwave ablation in a porcine tumormimic model[J]. Cardiovasc Intervent Radiol,2013,36(1):221-228.
[4] CARRAFIELLO G,IERARDI A M,FONTANA F,et al. Mi-crowave ablation of pancreatic head cancer:safety and efficacy[J]. J Vasc Interv Radiol,2013,24(10):1513-1520.
[5] YU Z,GENG J,ZHANG M,et al. Treatment of osteosarcomawith microwave thermal ablation to induce immunogenic celldeath[J]. Oncotarget,2014,5(15):6526-6539.
[6] ZHU J,YU M,CHEN L,et al. Enhanced antitumor efficacythrough microwave ablation in combination with immune check-points blockade in breast cancer:A pre-clinical study in a mu-rine model[J]. Diagn Interv Imaging,2018,99(3):135-142.
[7] NAKAYAMA J,KOKUBA H,KOBAYASHI J,et al. Experi-mental approaches for the treatment of murine B16 melanomasof various sizes. II:Injection of ethanol with combinations of be-ta-interferon and microwaval hyperthermia for B16 melanomaswith a size of greater than 10 mm in diameter[J]. J DermatolSci,1997,15(2):82-88.
[8] DONG B W,ZHANG J,LIANG P,et al. Sequential pathologi-cal and immunologic analysis of percutaneous microwave coagu-lation therapy of hepatocellular carcinoma[J]. Int J Hyperther-mia,2003,19(2):119-133.
[9] B?CKLUND M,FREEDMAN J. Microwave ablation and im-mune activation in the treatment of recurrent colorectal lung me-tastases:a case report[J]. Case Rep Oncol,2017,10(1):383-387.
[10] YANG X,YE X,ZHANG L,et al. Microwave ablation for lungcancer patients with a single lung:Clinical evaluation of 11 cas-es[J]. Thorac Cancer,2018,9(5):548-554.
[11] POGGI G,TOSORATTI N,MONTAGNA B,et al. Microwaveablation of hepatocellular carcinoma[J]. World J Hepatol,2015,31(25):2578-2589.
[12] AMOL M,RAHMI O,SHETH R A. Thermal ablative therapiesand immune checkpoint modulation:can locoregional approach-es effect a systemic response?[J]. Gastroenterol Res Pract,2016,2016(4):9251375.
[13] GROESCHL R T,PILGRIM C H,HANNA E M,et al. Micro-wave ablation for hepatic malignancies:a multiinstitutional anal-ysis[J]. Ann Surg,2014,259(6):1195-1200.
[14] SIMON C J,DUPUY D E,MAYO-SMITH W W. Microwave ab-lation:principles and applications[J]. Radiographics,2005,25(Suppl 1):S69-S83.
[15] KEISARI Y. Tumor abolition and antitumor immunostimulationby physico-chemical tumor ablation[J]. Front Biosci(Land-mark Ed),2017,22:310-347.
[16] CHANDRASEKARAN S,KING M R. Microenvironment of tu-mor-draining lymph nodes:opportunities for liposome-based tar-geted therapy[J]. Int J Mol Sci,2014,15(11):20209-20239.
[17] KUMAR V,PATEL S,TCYGANOV E,et al. The nature of my-eloid-derived suppressor cells in the tumor microenvironment[J]. Trends Immunol,2016,37(3):208-220.
[18] QU P,WANG L Z,LIN P C. Expansion and functions of my-eloid-derived suppressor cells in the tumor microenvironment[J]. Cancer Lett,2016,380(1):253-256.
[19] JADESKI L,HUM K C,LALA P. Nitric oxide promotes murinemammary tumour growth and metastasis by stimulating tumourcell migration,invasiveness and angiogenesis[J]. Int J Cancer,2000,86(1):30-39.
[20] WU F. Heat-based tumor ablation:role of the immune response[J]. Adv Exp Med Biol,2016,880:131-153.
[21] ZHU M,SUN Z,NG C K. Image-guided thermal ablation withMR-based thermometry[J]. Quant Imaging Med Surg,2017,7(3):356-368.
[22] WU H,CHEN B,PENG B. Effects of intratumoral injection ofimmunoactivator after microwave ablation on antitumor immunityin a mouse model of hepatocellular carcinoma[J]. Exp TherMed,2018,15(2):1914-1917.
[23] BASTIANPILLAI C,PETRIDES N,SHAH T,et al. Harness-ing the immunomodulatory effect of thermal and non-thermal ab-lative therapies for cancer treatment[J]. Tumour Biol,2015,36(12):9137-9146.
[24] LI L,WANG W,PAN H,et al. Microwave ablation combinedwith OK-432 induces Th1-type response and specific antitumorimmunity in a murine model of breast cancer[J]. J Transl Med,2017,15(1):23.
[25] ZHANG H,HOU X,CAI H,et al. Effects of microwave abla-tion on T-cell subsets and cytokines of patients with hepatocellu-lar carcinoma[J]. Minim Invasive Ther Allied Technol,2017,26(4):207-211.
[26] BEST J,SCHOTTEN C,THEYSOHN J M,et al. Novel impli-cations in the treatment of hepatocellular carcinoma[J]. AnnGastroenterol,2017,30(1):23-32.
[27] LI X,LIANG P. Immunotherapy for hepatocellular carcinomafollowing thermal ablation[J]. J BUON,2014,19(4):867-871.
[28] HAN X J,DONG B W,LIANG P,et al. The study of regionalcell immune response on ultrasonically guided microwave coagu-lation therapy for hepatocellular carcinoma and the influence oflymphocytic infiltration on clinical curative effect[J]. China On-cology,2007(02):135-138.
[29] MO Z,LU H,MO S,et al. Ultrasound-guided radiofrequencyablation enhances natural killer-mediated antitumor immunityagainst liver cancer[J]. Oncology Lett,2018,15(5):7014-7020.
[30] TAKAKI H,CORNELIS F,KAKO Y,et al. Thermal ablationand immunomodulation:From preclinical experiments to clini-cal trials[J]. Diagn Interv Imaging,2017,98(9):651-659.
[31] GARDINI A C,FOSCHI F G,CONTI F,et al. Immune inflam-mation indicators and ALBI score to predict occurrence and re-currence of hepatocellular carcinoma in HCV-related cirrhosistreated with direct-acting antivirals[J]. Dig Liver Dis,2018,50(1):50-51.
[32] KUREBAYASHI Y,OJIMA H,TSUJIKAWA H,et al. Land-scape of immune microenvironment in hepatocellular carcinomaand its additional impact on histological and molecular classifica-tion[J]. Hepatology,2018,doi:10.1002/hep.29904.
[33] LI Y,ZHU G,ZHAI H,et al. Simultaneous stimulation withtumor necrosis factor-αand transforming growth factor-β1 induc-es epithelial-mesenchymal transition in colon cancer cells viathe NF-κB pathway[J]. Oncol Lett,2018,15(5):6873-6880.
[34] BEDOSSA P,POYNARD T,MATHURIN P,et al. TGF-betalin situ expression in the liver of patients with chronic hepatitis Ctreated with alpha interferon[J]. Gut,1993,34(2 Suppl):S146-S147.
[35]曹兴国,魏强,俞海英,等.原发性肝癌微波消融治疗前后TNF-α和TGF-β1变化及其临床意义[J].肝脏,2013,18(5):319-321.
[36] SCHILLING D,GARRIDO C,COMBS S,et al. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tu-mor cells by Hsp90 inhibition[J]. Cancer Lett,2017,390:146-152.
[37] GAMMAZZA A M,CAMPANELLA C,BARONE R,et al.Doxorubicin anti-tumor mechanisms include Hsp60 post-transla-tional modifications leading to the Hsp60/p53 complex dissocia-tion and instauration of replicative senescence[J]. Cancer Lett,2016,385:75-86.
[38] SHAHROKHI S,DANESHMANDI S,MENAA F. Tumor necro-sis factor-α/CD40 ligand-engineered mesenchymal stem cellsgreatly enhanced the antitumor immune response and lifespan inmice[J]. Hum Gene Ther,2014,25(3):240-253.
[39] BOL K F,SCHREIBELT G,GERRITSEN W R,et al. Dendrit-ic Cell-Based Immunotherapy:State of the Art and Beyond[J].Clin Cancer Res,2016,22(8):1897-1906.
[40] SOMERSAN S,LARSSON M,FONTENEAU J F,et al. Prima-ry tumor tissue lysates are enriched in heat shock proteins andinduce the maturation of human dendritic cells[J]. J Immunol,2001,167(9):4844-4452.
[41] CANELLA A,WELKER A M,YOO J Y,et al. Efficacy ofonalespib,a long-acting second-generation HSP90 inhibitor,asa single agent and in combination with temozolomide against ma-lignant gliomas[J]. Clin Cancer Res,2017,23(20):6215-6226.
[42] FERRALDESCHI R,WELTI J,POWERS M V,et al. Second-generation HSP90 inhibitor onalespib blocks mRNA splicing ofandrogen receptor variant 7 in prostate cancer cells[J]. CancerRes,2016,76(9):2731-2742.
[43] JAQUE D,MARTíNEZ L M,DEL B R,et al. Nanoparticlesfor photothermal therapies.[J]. Nanoscale,2014,6(16):9494-9530.
[44] GUAN S Z,LIU J W,FANG E F,et al. Chronic unpredictablemild stress impairs erythrocyte immune function and changes T-lymphocyte subsets in a rat model of stress-induced depression[J]. Environ Toxicol Pharmacol,2014,37(1):414-422.
[45] WU D,SANIN D E,EVERTS B,et al. Type 1 interferons in-duce changes in core metabolism that are critical for immunefunction[J]. Immunity,2016,44(6):1325-1336.
[46] WANG D W,QING-JIU M A,XI-LIN D U,et al. Changes inerythrocyte immune functions and soluble Interleukin-2 in pa-tients with PHC after radiofrequency ablation[J]. Chin J Mod-ern Med,2004(02):67-69.
[2] FLORIDI C,DE B I,FONTANA F,et al. Microwave ablationof renal tumors:state of the art and development trends[J]. Ra-diol Med,2014,119(7):533-540.
[3] PLANCHéO,TERIITEHAU C,BOUDABOUS S,et al. In vi-vo evaluation of lung microwave ablation in a porcine tumormimic model[J]. Cardiovasc Intervent Radiol,2013,36(1):221-228.
[4] CARRAFIELLO G,IERARDI A M,FONTANA F,et al. Mi-crowave ablation of pancreatic head cancer:safety and efficacy[J]. J Vasc Interv Radiol,2013,24(10):1513-1520.
[5] YU Z,GENG J,ZHANG M,et al. Treatment of osteosarcomawith microwave thermal ablation to induce immunogenic celldeath[J]. Oncotarget,2014,5(15):6526-6539.
[6] ZHU J,YU M,CHEN L,et al. Enhanced antitumor efficacythrough microwave ablation in combination with immune check-points blockade in breast cancer:A pre-clinical study in a mu-rine model[J]. Diagn Interv Imaging,2018,99(3):135-142.
[7] NAKAYAMA J,KOKUBA H,KOBAYASHI J,et al. Experi-mental approaches for the treatment of murine B16 melanomasof various sizes. II:Injection of ethanol with combinations of be-ta-interferon and microwaval hyperthermia for B16 melanomaswith a size of greater than 10 mm in diameter[J]. J DermatolSci,1997,15(2):82-88.
[8] DONG B W,ZHANG J,LIANG P,et al. Sequential pathologi-cal and immunologic analysis of percutaneous microwave coagu-lation therapy of hepatocellular carcinoma[J]. Int J Hyperther-mia,2003,19(2):119-133.
[9] B?CKLUND M,FREEDMAN J. Microwave ablation and im-mune activation in the treatment of recurrent colorectal lung me-tastases:a case report[J]. Case Rep Oncol,2017,10(1):383-387.
[10] YANG X,YE X,ZHANG L,et al. Microwave ablation for lungcancer patients with a single lung:Clinical evaluation of 11 cas-es[J]. Thorac Cancer,2018,9(5):548-554.
[11] POGGI G,TOSORATTI N,MONTAGNA B,et al. Microwaveablation of hepatocellular carcinoma[J]. World J Hepatol,2015,31(25):2578-2589.
[12] AMOL M,RAHMI O,SHETH R A. Thermal ablative therapiesand immune checkpoint modulation:can locoregional approach-es effect a systemic response?[J]. Gastroenterol Res Pract,2016,2016(4):9251375.
[13] GROESCHL R T,PILGRIM C H,HANNA E M,et al. Micro-wave ablation for hepatic malignancies:a multiinstitutional anal-ysis[J]. Ann Surg,2014,259(6):1195-1200.
[14] SIMON C J,DUPUY D E,MAYO-SMITH W W. Microwave ab-lation:principles and applications[J]. Radiographics,2005,25(Suppl 1):S69-S83.
[15] KEISARI Y. Tumor abolition and antitumor immunostimulationby physico-chemical tumor ablation[J]. Front Biosci(Land-mark Ed),2017,22:310-347.
[16] CHANDRASEKARAN S,KING M R. Microenvironment of tu-mor-draining lymph nodes:opportunities for liposome-based tar-geted therapy[J]. Int J Mol Sci,2014,15(11):20209-20239.
[17] KUMAR V,PATEL S,TCYGANOV E,et al. The nature of my-eloid-derived suppressor cells in the tumor microenvironment[J]. Trends Immunol,2016,37(3):208-220.
[18] QU P,WANG L Z,LIN P C. Expansion and functions of my-eloid-derived suppressor cells in the tumor microenvironment[J]. Cancer Lett,2016,380(1):253-256.
[19] JADESKI L,HUM K C,LALA P. Nitric oxide promotes murinemammary tumour growth and metastasis by stimulating tumourcell migration,invasiveness and angiogenesis[J]. Int J Cancer,2000,86(1):30-39.
[20] WU F. Heat-based tumor ablation:role of the immune response[J]. Adv Exp Med Biol,2016,880:131-153.
[21] ZHU M,SUN Z,NG C K. Image-guided thermal ablation withMR-based thermometry[J]. Quant Imaging Med Surg,2017,7(3):356-368.
[22] WU H,CHEN B,PENG B. Effects of intratumoral injection ofimmunoactivator after microwave ablation on antitumor immunityin a mouse model of hepatocellular carcinoma[J]. Exp TherMed,2018,15(2):1914-1917.
[23] BASTIANPILLAI C,PETRIDES N,SHAH T,et al. Harness-ing the immunomodulatory effect of thermal and non-thermal ab-lative therapies for cancer treatment[J]. Tumour Biol,2015,36(12):9137-9146.
[24] LI L,WANG W,PAN H,et al. Microwave ablation combinedwith OK-432 induces Th1-type response and specific antitumorimmunity in a murine model of breast cancer[J]. J Transl Med,2017,15(1):23.
[25] ZHANG H,HOU X,CAI H,et al. Effects of microwave abla-tion on T-cell subsets and cytokines of patients with hepatocellu-lar carcinoma[J]. Minim Invasive Ther Allied Technol,2017,26(4):207-211.
[26] BEST J,SCHOTTEN C,THEYSOHN J M,et al. Novel impli-cations in the treatment of hepatocellular carcinoma[J]. AnnGastroenterol,2017,30(1):23-32.
[27] LI X,LIANG P. Immunotherapy for hepatocellular carcinomafollowing thermal ablation[J]. J BUON,2014,19(4):867-871.
[28] HAN X J,DONG B W,LIANG P,et al. The study of regionalcell immune response on ultrasonically guided microwave coagu-lation therapy for hepatocellular carcinoma and the influence oflymphocytic infiltration on clinical curative effect[J]. China On-cology,2007(02):135-138.
[29] MO Z,LU H,MO S,et al. Ultrasound-guided radiofrequencyablation enhances natural killer-mediated antitumor immunityagainst liver cancer[J]. Oncology Lett,2018,15(5):7014-7020.
[30] TAKAKI H,CORNELIS F,KAKO Y,et al. Thermal ablationand immunomodulation:From preclinical experiments to clini-cal trials[J]. Diagn Interv Imaging,2017,98(9):651-659.
[31] GARDINI A C,FOSCHI F G,CONTI F,et al. Immune inflam-mation indicators and ALBI score to predict occurrence and re-currence of hepatocellular carcinoma in HCV-related cirrhosistreated with direct-acting antivirals[J]. Dig Liver Dis,2018,50(1):50-51.
[32] KUREBAYASHI Y,OJIMA H,TSUJIKAWA H,et al. Land-scape of immune microenvironment in hepatocellular carcinomaand its additional impact on histological and molecular classifica-tion[J]. Hepatology,2018,doi:10.1002/hep.29904.
[33] LI Y,ZHU G,ZHAI H,et al. Simultaneous stimulation withtumor necrosis factor-αand transforming growth factor-β1 induc-es epithelial-mesenchymal transition in colon cancer cells viathe NF-κB pathway[J]. Oncol Lett,2018,15(5):6873-6880.
[34] BEDOSSA P,POYNARD T,MATHURIN P,et al. TGF-betalin situ expression in the liver of patients with chronic hepatitis Ctreated with alpha interferon[J]. Gut,1993,34(2 Suppl):S146-S147.
[35]曹兴国,魏强,俞海英,等.原发性肝癌微波消融治疗前后TNF-α和TGF-β1变化及其临床意义[J].肝脏,2013,18(5):319-321.
[36] SCHILLING D,GARRIDO C,COMBS S,et al. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tu-mor cells by Hsp90 inhibition[J]. Cancer Lett,2017,390:146-152.
[37] GAMMAZZA A M,CAMPANELLA C,BARONE R,et al.Doxorubicin anti-tumor mechanisms include Hsp60 post-transla-tional modifications leading to the Hsp60/p53 complex dissocia-tion and instauration of replicative senescence[J]. Cancer Lett,2016,385:75-86.
[38] SHAHROKHI S,DANESHMANDI S,MENAA F. Tumor necro-sis factor-α/CD40 ligand-engineered mesenchymal stem cellsgreatly enhanced the antitumor immune response and lifespan inmice[J]. Hum Gene Ther,2014,25(3):240-253.
[39] BOL K F,SCHREIBELT G,GERRITSEN W R,et al. Dendrit-ic Cell-Based Immunotherapy:State of the Art and Beyond[J].Clin Cancer Res,2016,22(8):1897-1906.
[40] SOMERSAN S,LARSSON M,FONTENEAU J F,et al. Prima-ry tumor tissue lysates are enriched in heat shock proteins andinduce the maturation of human dendritic cells[J]. J Immunol,2001,167(9):4844-4452.
[41] CANELLA A,WELKER A M,YOO J Y,et al. Efficacy ofonalespib,a long-acting second-generation HSP90 inhibitor,asa single agent and in combination with temozolomide against ma-lignant gliomas[J]. Clin Cancer Res,2017,23(20):6215-6226.
[42] FERRALDESCHI R,WELTI J,POWERS M V,et al. Second-generation HSP90 inhibitor onalespib blocks mRNA splicing ofandrogen receptor variant 7 in prostate cancer cells[J]. CancerRes,2016,76(9):2731-2742.
[43] JAQUE D,MARTíNEZ L M,DEL B R,et al. Nanoparticlesfor photothermal therapies.[J]. Nanoscale,2014,6(16):9494-9530.
[44] GUAN S Z,LIU J W,FANG E F,et al. Chronic unpredictablemild stress impairs erythrocyte immune function and changes T-lymphocyte subsets in a rat model of stress-induced depression[J]. Environ Toxicol Pharmacol,2014,37(1):414-422.
[45] WU D,SANIN D E,EVERTS B,et al. Type 1 interferons in-duce changes in core metabolism that are critical for immunefunction[J]. Immunity,2016,44(6):1325-1336.
[46] WANG D W,QING-JIU M A,XI-LIN D U,et al. Changes inerythrocyte immune functions and soluble Interleukin-2 in pa-tients with PHC after radiofrequency ablation[J]. Chin J Mod-ern Med,2004(02):67-69.